Direct thrombin inhibitors during PCI.
Satler
Lowell F
LF
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000379:methods; D000925:Anticoagulants / Q000008:administration & dosage; D001120:Arginine / Q000031:analogs & derivatives; D023921:Coronary Stenosis / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy*; D003328:Coronary Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D010875:Pipecolic Acids / Q000008:administration & dosage*; D011859:Radiography; D018570:Risk Assessment; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications; D016896:Treatment Outcome
D000925:Anticoagulants; D010875:Pipecolic Acids; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; C031942:argatroban